• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Hutchison MediPharma Limited - Product Pipeline Review - Q4 2010 Product Image

Hutchison MediPharma Limited - Product Pipeline Review - Q4 2010

  • ID: 1446471
  • November 2010
  • 46 pages
  • GlobalData

Hutchison MediPharma Limited – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Hutchison MediPharma Limited - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Hutchison MediPharma Limited - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hutchison MediPharma Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Hutchison MediPharma Limited Snapshot
Hutchison MediPharma Limited Overview
Key Information
Key Facts
Hutchison MediPharma Limited – Research and Development Overview
Key Therapeutic Areas
Hutchison MediPharma Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Hutchison MediPharma Limited – Pipeline Products Glance
Hutchison MediPharma Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Hutchison MediPharma Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Hutchison MediPharma Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Hutchison MediPharma Limited – Drug Profiles
HMPL-004
Product Description
Mechanism of Action
R&D Progress
HMPL-004
Product Description
Mechanism of Action
R&D Progress
HMPL-011
Product Description
Mechanism of Action
R&D Progress
HMPL-012
Product Description
Mechanism of Action
R&D Progress
HMPL-013
Product Description
Mechanism of Action
R&D Progress
HMPL-342
Product Description
Mechanism of Action
R&D Progress
HMPL-813
Product Description
Mechanism of Action
R&D Progress
HMPL-309
Product Description
Mechanism of Action
R&D Progress
Hutchison MediPharma Limited – Pipeline Analysis
Hutchison MediPharma Limited – Pipeline Products by Therapeutic Class
Hutchison MediPharma Limited Pipeline Products By Target
Hutchison MediPharma Limited – Pipeline Products by Route of Administration
Hutchison MediPharma Limited – Pipeline Products by Molecule Type
Hutchison MediPharma Limited - Dormant Projects
Hutchison MediPharma Limited – Locations And Subsidiaries
Head Office
Recent Developments
Mar 09, 2010: HMPL-004 Ulcerative Colitis Results Selected for Distinguished Plenary Oral Presentation during Digestive Disease Week Conference
Nov 05, 2009: Hutchison MediPharma Limited Achieves Successful Global Phase IIb Ulcerative Colitis Trial For HMPL-004
Oct 30, 2009: Initiated Phase I Clinical Trial Of HMPL-011, Its Novel Single Chemical Drug Candidate For The Treatment Of Autoimmune Diseases
Oct 30, 2009: Initiated Phase I Clinical Trial Of HMPL-011, Its Novel Single Chemical Drug Candidate For The Treatment Of Autoimmune Diseases
Oct 30, 2009: Initiated Phase I Clinical Trial Of HMPL-011, Its Novel Single Chemical Drug Candidate For The Treatment Of Autoimmune Diseases
Jul 29, 2009: Hutchison MediPharma Completes Patient Enrollment Ahead Of Schedule For HMPL-004’s Global Phase IIb Trial For Ulcerative Colitis
Jul 19, 2009: Hutchison MediPharma Announces Encouraging Results From Crohn's Disease Phase II Trial For HMPL-004
Jan 08, 2009: Hutchison China-Medicine Presents HMPL-002 Clinical Trial Update
Jan 08, 2009: Hutchison China-Medicine Presents HMPL-002 Clinical Trial Update
Feb 29, 2008: Patient Enrollment Started in Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate
Financial Deals Landscape
Hutchison MediPharma Limited, Deals Volume Summary, 2004 to YTD 2010
Hutchison MediPharma Limited, Deals Summary By Region, 2004 to YTD 2010
Hutchison MediPharma Limited, Deals Summary, 2004 to YTD 2010
Hutchison MediPharma Limited Detailed Deal Summary
Hutchison MediPharma Enters Into Co-Development Agreement With Ortho-McNeil-Janssen
Hutchison MediPharma Expands Co-Development Agreement With Eli Lilly
Hutchison MediPharma Enters Into Agreement With Eli Lilly
Hutchison MediPharma Enters Into Research Collaboration With Merck
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS